Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 262

Sort by

Sort Order Select

Meeting Abstracts

95-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects —A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study

JINGYING WU, WEI HU, YIJUN DU, QIAN ZHANG, RENPENG ZHOU, QIN ZHANG, HUILING QIN, ZI YE, YIMEI XU, SHENG FENG, CHANG SHU, YU SHEN, YANG FAN

Diabetes 2023;72(Supplement_1):95-LB

https://doi.org/10.2337/db23-95-LB

Published: 20 June 2023

View article titled, 95-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects —A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study

Meeting Abstracts

273-LB: The Effect of Bispecific GLP-1R/GLP-2R Agonist Compared with Dual GLP-1R/GLP-2R Agonist and Dual GLP-1R/GIPR Agonist in Diet-Induced Obesity Mouse Model

TIMOTHY OH, SANG-IN YANG, JAEIL ROH, JEE YOON SUNG

Diabetes 2023;72(Supplement_1):273-LB

https://doi.org/10.2337/db23-273-LB

Published: 20 June 2023

View article titled, 273-LB: The Effect of Bispecific GLP-1R/GLP-2R Agonist Compared with Dual GLP-1R/GLP-2R Agonist and Dual GLP-1R/GIPR Agonist in Diet-Induced Obesity Mouse Model

Meeting Abstracts

1559-P: Glucagon Receptor–Mediated Improvements in Glycemia Are Dependent on Agonist Pharmacodynamics

SHELLY NASON, TEAYOUN KIM, JESSICA ANTIPENKO, BIN YANG, RICHARD DIMARCHI, KIRK M. HABEGGER

Diabetes 2023;72(Supplement_1):1559-P

https://doi.org/10.2337/db23-1559-P

Published: 20 June 2023

View article titled, 1559-P: Glucagon Receptor–Mediated Improvements in Glycemia Are Dependent on Agonist Pharmacodynamics

Meeting Abstracts

72-LB: DD01, a Novel Once-Weekly Dual GLP-1/Glucagon Receptor Agonist, Improves Metabolic Health and Achieves Rapid, Clinically Significant Reductions in Hepatic Steatosis following Only Four Weeks of Treatment and without the Need for Significant Weight Loss in Overweight/Diabetic Subjects with NAFLD

DENNIS TO, JAEHEE SHIN, SUBBU KARANTH, YEN-HUEI LIN, SVETLANA SOSNOVTSEVA, ADAM C. BELL

Diabetes 2023;72(Supplement_1):72-LB

https://doi.org/10.2337/db23-72-LB

Published: 20 June 2023

View article titled, 72-LB: DD01, a Novel Once-Weekly Dual GLP-1/Glucagon Receptor Agonist, Improves Metabolic Health and Achieves Rapid, Clinically Significant Reductions in Hepatic Steatosis following Only Four Weeks of Treatment and without the Need for Significant Weight Loss in Overweight/Diabetic Subjects with NAFLD

Meeting Abstracts

840-P: Dual Amylin and Calcitonin Receptor Agonist Treatment Improves Blood Pressure and Glucose Control in ZSF1 Rats

SIMONE A. MELANDER, ANNA T. LARSEN, KHALED ELHADY MOHAMED, MORTEN A. KARSDAL, KIM HENRIKSEN

Diabetes 2023;72(Supplement_1):840-P

https://doi.org/10.2337/db23-840-P

Published: 20 June 2023

View article titled, 840-P: Dual Amylin and Calcitonin Receptor Agonist Treatment Improves Blood Pressure and Glucose Control in ZSF1 Rats

Meeting Abstracts

1676-P: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats

YUNA CHAE, TAE-HYOUNG KIM, IL-HUN JUNG, HYUNG HEON KIM, MI-KYUNG KIM

Diabetes 2023;72(Supplement_1):1676-P

https://doi.org/10.2337/db23-1676-P

Published: 20 June 2023

View article titled, 1676-P: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats

Meeting Abstracts

313-OR: The Efficacy and Safety of Glucagon-Like-Peptide-1 Agonists in Patients with Familial Partial Lipodystrophy

SALMAN K. IMAM, MARIA C. FOSS-FREITAS, RASIMCAN MERAL, ELIF A. ORAL, ANABELA DILL GOMES, FATIHA GRISSI

Diabetes 2023;72(Supplement_1):313-OR

https://doi.org/10.2337/db23-313-OR

Published: 20 June 2023

View article titled, 313-OR: The Efficacy and Safety of Glucagon-Like-Peptide-1 Agonists in Patients with Familial Partial Lipodystrophy

Meeting Abstracts

208-OR: Comparable Improvement in NAFLD, Weight Loss, and Lipid Metabolism in Rats Treated with Dual GLP-1–GIP Receptor Agonist (Tirzepatide) and Gastric Sleeve

JEHAD ABUBAKER, SALMAN ALSABAH, IRINA AL-KHAIRI, PREETHI T. CHERIAN, NERMEEN A. ABUKHALAF, HOSSEIN AREFANIAN, CAROL DSOUZA, SR., SULEIMAN AL-SABAH, FAHD AL-MULLA, MOHAMED ABU-FARHA

Diabetes 2023;72(Supplement_1):208-OR

https://doi.org/10.2337/db23-208-OR

Published: 20 June 2023

View article titled, 208-OR: Comparable Improvement in NAFLD, Weight Loss, and Lipid Metabolism in Rats Treated with Dual GLP-1–GIP Receptor Agonist (Tirzepatide) and Gastric Sleeve

Meeting Abstracts

77-LB: A Novel Glucagon-Like Peptide-1 (GLP-1R) and Glucagon (GCGR) Receptor Dual Agonist, Mazdutide (IBI362), Attenuates Hyperuricemia in Hyperuricemic Rats

HONGWEI JIANG, YANZHAO ZHANG, YAN SHUANG REN

Diabetes 2023;72(Supplement_1):77-LB

https://doi.org/10.2337/db23-77-LB

Published: 20 June 2023

View article titled, 77-LB: A Novel Glucagon-Like Peptide-1 (GLP-1R) and Glucagon (GCGR) Receptor Dual Agonist, Mazdutide (IBI362), Attenuates Hyperuricemia in Hyperuricemic Rats

Meeting Abstracts

749-P: Selection of BI 456906 as a Dual GCGR/GLP-1R Agonist Based on In Vitro Potency and In Vivo Target Engagement Biomarkers

ROBERT AUGUSTIN, LEO THOMAS, TINA ZIMMERMANN, ERIC SIMON, WOLFGANG RIST, INGO UPHUES, WOLFGANG REINDL, THOMAS KLEIN, HEIKE NEUBAUER

Diabetes 2023;72(Supplement_1):749-P

https://doi.org/10.2337/db23-749-P

Published: 20 June 2023

View article titled, 749-P: Selection of BI 456906 as a Dual GCGR/GLP-1R Agonist Based on In Vitro Potency and In Vivo Target Engagement Biomarkers

Meeting Abstracts

211-OR: Dual Amylin and Calcitonin Receptor Agonists Increase Mitochondrial Respiratory Capacity in Adipose Tissues of Obese Rat

EMILIE A. PETERSEN, IDA BLOM, SIMONE A. MELANDER, MORTEN A. KARSDAL, STEEN LARSEN, KIM HENRIKSEN, ANNA T. LARSEN

Diabetes 2023;72(Supplement_1):211-OR

https://doi.org/10.2337/db23-211-OR

Published: 20 June 2023

View article titled, 211-OR: Dual Amylin and Calcitonin Receptor Agonists Increase Mitochondrial Respiratory Capacity in Adipose Tissues of Obese Rat

Meeting Abstracts

1588-P: Translatable Modeling of Glucagon Actions in Human iPSC-Derived Hepatocytes Uniquely Predicts Differential Clinical Responses to Glucagon Analog Agonist Molecules

WILLIAM ROELL, AJIT REGMI, CHARLES T. BENSON, TAMER COSKUN, JULIE S. MOYERS, JORGE ALSINA-FERNANDEZ, MELISSA K. THOMAS

Diabetes 2023;72(Supplement_1):1588-P

https://doi.org/10.2337/db23-1588-P

Published: 20 June 2023

View article titled, 1588-P: Translatable Modeling of Glucagon Actions in Human iPSC-Derived Hepatocytes Uniquely Predicts Differential Clinical Responses to Glucagon Analog Agonist Molecules

Meeting Abstracts

861-P: The Effect of Dual Amylin and Calcitonin Receptor Agonist Treatment on Spatial Memory in Rat Models of Metabolic Syndrome

KHALED ELHADY MOHAMED, ANNA T. LARSEN, SIMONE A. MELANDER, MORTEN A. KARSDAL, KIM HENRIKSEN

Diabetes 2023;72(Supplement_1):861-P

https://doi.org/10.2337/db23-861-P

Published: 20 June 2023

View article titled, 861-P: The Effect of Dual Amylin and Calcitonin Receptor Agonist Treatment on Spatial Memory in Rat Models of Metabolic Syndrome

Meeting Abstracts

763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study

KUN HE, FANG WEI, HONG CHEN, YANYAN ZHANG, ZHEN SHENG, QING WEN

Diabetes 2023;72(Supplement_1):763-P

https://doi.org/10.2337/db23-763-P

Published: 20 June 2023

View article titled, 763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study

Meeting Abstracts

1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist

YUNA CHAE, IL-HUN JUNG, TAE-HYOUNG KIM, SU JIN LEE, MI-KYUNG KIM, HYUNG HEON KIM

Diabetes 2023;72(Supplement_1):1668-P

https://doi.org/10.2337/db23-1668-P

Published: 20 June 2023

View article titled, 1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist

Meeting Abstracts

284-OR: An Alternative Downstream Translational Start Site in PPARG Produces a Novel Protein That Rescues Loss-of-Function Mutations in Humans

KAREN MENDEZ LARA, XIAOMI DU, KIMBERLY GLASS, RUBEN HERNANDEZ, CAMILA DE ARRUDA SALDANHA, SVEN HEINZ, AMIT R. MAJITHIA

Diabetes 2023;72(Supplement_1):284-OR

https://doi.org/10.2337/db23-284-OR

Published: 20 June 2023

View article titled, 284-OR: An Alternative Downstream Translational Start Site in PPARG Produces a Novel Protein That Rescues Loss-of-Function Mutations in Humans

Meeting Abstracts

80-LB: Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist Delivered through the BIOJET Oral Biotherapeutic Delivery Platform in Porcine Model

SHAOYING N. LEE, CHERYL A. STORK, RENE O. VALENZUELA-RIVAS, MICHELLE WALKER, BRYAN J. SMITH, JEFFREY A. SMITH, NELSON QUINTANA, CHRIS WAHL, SHARAT SINGH

Diabetes 2023;72(Supplement_1):80-LB

https://doi.org/10.2337/db23-80-LB

Published: 20 June 2023

View article titled, 80-LB: Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist Delivered through the BIOJET Oral Biotherapeutic Delivery Platform in Porcine Model

Meeting Abstracts

267-OR: ADA Presidents' Select Abstract: Combining an SGLT Inhibitor with a Glucagon Receptor Agonist (GRA) in Subjects with Type 1 Diabetes—A Randomized Clinical Trial

SCHAFER C. BOEDER, MELISSA J. LE ROUX, ERIN R. GIOVANNETTI, ADRIENNE ARMSTRONG, LESLIE CARTER, ROBERT L. THOMAS, JUSTIN M. GREGORY, JEREMY PETTUS

Diabetes 2023;72(Supplement_1):267-OR

https://doi.org/10.2337/db23-267-OR

Published: 20 June 2023

View article titled, 267-OR: ADA Presidents' Select Abstract: Combining an SGLT Inhibitor with a Glucagon Receptor Agonist (GRA) in Subjects with Type 1 Diabetes—A Randomized Clinical Trial

Meeting Abstracts

6-LB: GPR119 Agonist PRM A Increases Glucagon Response to Hypoglycemia in Rats

DAVID W.K. KWOK, DIANE ALEXANDER, NIGEL R.A. BEELEY, DAVID KELLEY

Diabetes 2023;72(Supplement_1):6-LB

https://doi.org/10.2337/db23-6-LB

Published: 20 June 2023

View article titled, 6-LB: GPR119 Agonist PRM A Increases Glucagon Response to Hypoglycemia in Rats

Meeting Abstracts

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

FILIP K. KNOP, SHWETA URVA, MALLIKARJUNA RETTIGANTI, CHARLES BENSON, WILLIAM ROELL, KIEREN J. MATHER, AXEL HAUPT, EDWARD J. PRATT

Diabetes 2023;72(Supplement_1):56-OR

https://doi.org/10.2337/db23-56-OR

Published: 20 June 2023

View article titled, 56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

NARROW

95-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects —A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study

273-LB: The Effect of Bispecific GLP-1R/GLP-2R Agonist Compared with Dual GLP-1R/GLP-2R Agonist and Dual GLP-1R/GIPR Agonist in Diet-Induced Obesity Mouse Model

1559-P: Glucagon Receptor–Mediated Improvements in Glycemia Are Dependent on Agonist Pharmacodynamics

840-P: Dual Amylin and Calcitonin Receptor Agonist Treatment Improves Blood Pressure and Glucose Control in ZSF1 Rats

1676-P: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats

313-OR: The Efficacy and Safety of Glucagon-Like-Peptide-1 Agonists in Patients with Familial Partial Lipodystrophy

208-OR: Comparable Improvement in NAFLD, Weight Loss, and Lipid Metabolism in Rats Treated with Dual GLP-1–GIP Receptor Agonist (Tirzepatide) and Gastric Sleeve

77-LB: A Novel Glucagon-Like Peptide-1 (GLP-1R) and Glucagon (GCGR) Receptor Dual Agonist, Mazdutide (IBI362), Attenuates Hyperuricemia in Hyperuricemic Rats

749-P: Selection of BI 456906 as a Dual GCGR/GLP-1R Agonist Based on In Vitro Potency and In Vivo Target Engagement Biomarkers

211-OR: Dual Amylin and Calcitonin Receptor Agonists Increase Mitochondrial Respiratory Capacity in Adipose Tissues of Obese Rat

1588-P: Translatable Modeling of Glucagon Actions in Human iPSC-Derived Hepatocytes Uniquely Predicts Differential Clinical Responses to Glucagon Analog Agonist Molecules

861-P: The Effect of Dual Amylin and Calcitonin Receptor Agonist Treatment on Spatial Memory in Rat Models of Metabolic Syndrome

763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study

1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist

284-OR: An Alternative Downstream Translational Start Site in PPARG Produces a Novel Protein That Rescues Loss-of-Function Mutations in Humans

80-LB: Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist Delivered through the BIOJET Oral Biotherapeutic Delivery Platform in Porcine Model

267-OR: ADA Presidents' Select Abstract: Combining an SGLT Inhibitor with a Glucagon Receptor Agonist (GRA) in Subjects with Type 1 Diabetes—A Randomized Clinical Trial

6-LB: GPR119 Agonist PRM A Increases Glucagon Response to Hypoglycemia in Rats

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only